IL-6 binding molecules

US11827701B2 · kind B2 · utility

Assignee

• argenx BV · BE

Inventors

• Christophe Blanchetot · Laarne, BE
• Johannes Joseph Wilhelmus De Haard · Vlaardingen, NL
• Torsten Dreier · Breda, NL
• Natalie De Jonge · Zwijnaarde, BE
• Sebastian Van Der Woning · Deinze, BE
• Nicolas Ongenae · Wondelgem, BE

Key dates

• Filing date: Aug 10, 2021
• Grant date: Nov 28, 2023
• Expiry date: Nov 6, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).